Key points are not available for this paper at this time.
IDH1 mutations are a strong predictor of a more favorable prognosis and a highly selective molecular marker of secondary glioblastomas that complements clinical criteria for distinguishing them from primary glioblastomas.
Nobusawa et al. (Tue,) studied this question.